We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$184M
Cap. Flow
+$269M
Cap. Flow %
24.82%
Top 10 Hldgs %
42.57%
Holding
126
New
25
Increased
29
Reduced
26
Closed
35

Top Buys

Rank Stock Value
1
TMCI icon
Treace Medical Concepts
TMCI
+$34.9M
2
TGTX icon
TG Therapeutics
TGTX
+$34.1M
3
GSK icon
GSK
GSK
+$33.5M
4
PODD icon
Insulet
PODD
+$28.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$23.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$13.7M
3
ACLX
Arcellx
ACLX
+$12.3M
4
CVS icon
CVS Health
CVS
+$11.5M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.02%
2 Consumer Staples 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
101
DexCom
DXCM
$32B
– –
-33,000
Closed -$4.24M
ILMN icon
102
Illumina
ILMN
$28.4B
– –
-47,185
Closed -$8.61M
IMCR icon
103
Immunocore
IMCR
$1.73B
– –
-16,400
Closed -$983K
INDV icon
104
Indivior Pharmaceuticals
INDV
$4.58B
– –
-18,624
Closed -$443K
LLY icon
105
Eli Lilly
LLY
$1.06T
– –
-4,300
Closed -$2.02M
LUNG icon
106
Pulmonx
LUNG
$87.6M
– –
-41,000
Closed -$538K
MLYS icon
107
Mineralys Therapeutics
MLYS
$2.41B
– –
-76,817
Closed -$1.31M
PLRX icon
108
Pliant Therapeutics
PLRX
$65M
– –
-33,500
Closed -$607K
PTGX icon
109
Protagonist Therapeutics
PTGX
$9.44B
– –
-39,800
Closed -$1.1M
RYTM icon
110
Rhythm Pharmaceuticals
RYTM
$7.96B
– –
-38,600
Closed -$637K
STRO icon
111
Sutro Biopharma
STRO
$421M
– –
-2,589
Closed -$120K
TMDX icon
112
Transmedics
TMDX
$2.91B
– –
-74,200
Closed -$6.23M
TVTX icon
113
Travere Therapeutics
TVTX
$5.78B
– –
-21,600
Closed -$332K
TWST icon
114
Twist Bioscience
TWST
$7.25B
– –
-160,000
Closed -$3.27M
VCEL icon
115
Vericel Corp
VCEL
$2.31B
– –
-67,049
Closed -$2.52M
VRDN icon
116
Viridian Therapeutics
VRDN
$2.67B
– –
-34,000
Closed -$809K
VRNA
117
DELISTED
Verona Pharma
VRNA
– –
-21,700
Closed -$459K
VTYX
118
DELISTED
Ventyx Biosciences
VTYX
– –
-21,300
Closed -$699K
FNA
119
DELISTED
Paragon 28, Inc.
FNA
– –
-10,000
Closed -$177K
MORF
120
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-13,600
Closed -$780K
CERE
121
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-46,000
Closed -$1.46M
CBAY
122
DELISTED
Cymabay Therapeutics
CBAY
– –
-373,000
Closed -$4.08M
SGEN
123
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-71,000
Closed -$13.7M
RETA
124
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-97,547
Closed -$9.95M
DICE
125
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-80,000
Closed -$3.72M
2 3 4
5
6

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Soleus Capital Management held 126 positions worth $1.08B, up 20% from $900M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management deployed $269M of net new capital in Q3 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Treace Medical Concepts: 1,907,823 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $23.3M trimmed.

  • Soleus Capital Management's largest Q3 2023 buy was Treace Medical Concepts: 1,907,823 shares worth $25M.
  • Soleus Capital Management added most to TG Therapeutics in Q3 2023, an estimated $34.1M increase.
  • Soleus Capital Management's biggest Q3 2023 reduction was Charles River Laboratories, cutting an estimated $23.3M.
  • Soleus Capital Management fully exited Seagen Inc. Common Stock in Q3 2023, selling an estimated $13.7M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $1.08B portfolio in Q3 2023.
  • Soleus Capital Management opened 25 new positions and closed 35 in Q3 2023.
  • Soleus Capital Management's portfolio value rose 20% quarter-over-quarter to $1.08B.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.